Wilmington, Delaware, United States, Sept. 07, 2023 (GLOBE NEWSWIRE) -- The global market for short bowel syndrome was estimated to have acquired US$ 260 million in 2020. It is anticipated to advance with a rapid 27% CAGR from 2021 to 2031 and by 2031, the market is likely to gain US$ 3.66 billion.
An organ transplant or long-term parenteral feeding are needed to treat short bowel syndrome (SBS). The latter is related to the organ scarcity since the outcome of the previous therapy is unknown. Scientists working on the EU-funded INTENS project are attempting to provide a superior alternative.
Companies in the market for short bowel syndrome are emulating these researchers in order to establish a strategy for autologous tissue engineering, often known as the practice of treating a person using their own cells or tissues.
In a nutshell, the Transparency Market Research Report is essential reading for start-ups, individuals in the industry, investors, researchers, consultants, business strategists, and anyone seeking to gain insight into this particular sector. Take a brief look at it: https://www.transparencymarketresearch.com/short-bowel-syndrome-market.html
Market Snapshot:
| Report Coverage | Details | |
| Market Revenue | US$ 728.3 Mn | |
| Estimated Value | US$ 3.66 Bn | |
| Growth Rate - CAGR | 15.9% | |
| Forecast Period | 2021-2031 | |
| No. of Pages | 158 Pages | |
| Market Segmentation | Product, Distribution Channel, Region | |
| Regions Covered | North America, Europe, Asia Pacific, Middle East & Africa, South America | |
| Companies Covered | Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc. | |
Key Findings of the Market Report
- In 2021, a sizable portion of the distribution channel segment's revenue is anticipated to come from online and retail pharmacies.
- The dominance is attributable to the rise in retail and online pharmacies in nations like the United States, the United Kingdom, India, and others.
- A large variety of GLP-2-based pipeline items for short bowel syndrome is the primary reason for the GLP-2 segment's dominance.
- Hospital pharmacies are anticipated to occupy a sizable portion of the market due to the industry's growing need for cutting-edge medications to treat ailments like Crohn's disease, one of the leading causes of short bowel syndrome.
Market Trends for Short Bowel Syndrome
- Over the past several years, small bowel syndrome has become more common everywhere. The rise in patients receiving whole parenteral nourishment can be blamed for this. Short bowel syndrome is predicted to have a prevalence of four cases per million and an incidence of three cases per million.
- The precise incidence of the illness is unknown, and it is assumed based on the number of persons receiving parenteral feeding. The rise in frequency and incidence of uncommon diseases is probably what will drive the global market's expansion.
- There are now many additional treatments being tested in clinical trials for the management of short bowel syndrome, and there are no approved medications for the illness worldwide.
The market's best insights begin with a simple request – get your sample now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346
Short Bowel Syndrome Market Regional Outlook
Various reasons are propelling the growth of the short bowel syndrome market in different regions. These are:
- The expansion of the short bowel syndrome market in North America is being driven by the presence of a sizable patient pool embracing cutting-edge medications and needing new treatment alternatives. It is projected that the availability of a broad variety of pipeline items as well as the extended usage of authorized pharmaceuticals to treat adults as well as kids would support market growth in this area over the course of the projection period.
- Asia Pacific is predicted to have the most rapid CAGR throughout the projection period. The market expansion in this area is fueled by the direct participation of large companies, substantial investments in research and development for the creation of novel pharmaceuticals, and a growing emphasis on GLP-2-based medication clinical trials.
Global Short Bowel Syndrome Market: Key Players
Market players for short bowel syndrome are involved in regulatory approvals, the creation of new services, acquisitions, and joint ventures with other businesses. The short bowel syndrome market will probably grow internationally as a result of these tactics over the coming years.
The following companies are well-known participants in the global short bowel syndrome market:
- Takeda Pharmaceutical Company Limited
- Merck KGaA
- Zealand Pharma A/S
- OxThera
- VectivBio AG
- 9 Meters Biopharma, Inc.
- Nutrinia Ltd.
- Hanmi Pharm.Co., Ltd.
- Pharmascience, Inc.
Key developments in the global market for short bowel syndrome are:
| Market Player | Year | Key Developments |
| VectivBio Holding AG | 2021 |
|
| Hanmi Pharm. Co. Ltd. | 2021 |
|
For Customization or Any Other Queries, Get in Touch with Our Industry Experts at - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=13346
Global Short Bowel Syndrome Market Segmentation
Product
- Glucagon-like Peptide-2 (GLP2)
- Growth Hormone
- Glutamine
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
Region
- North America
- Europe
- Japan
- Australia
- Rest of the World
Transparency Market Research constantly tracks industry trends. Some relevant market reports from the analysts that might be of interest to you:
Demand for Surgical Kits - Market Size, Trends, Analysis, Scope, Growth Drivers
Medical Refrigeration Market Size [2023-2031] | Industry Share, Growth
Lyophilized Injectable Market Size, Growth Analysis, Future Scenario 2023-2031
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com
